Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Ansun Starts US Proof-of-Concept Trial for COVID-19 Treatment

publication date: Apr 15, 2020

Ansun Biopharma, a San Diego biopharma, enrolled the first patient in a US proof-of-concept study to evaluate the safety and efficacy of its treatment for severe COVID-19 infection. DAS181 is a recombinant sialidase protein that cleaves sialic acid located on epithelial cells that line the respiratory tract, blocking virus entry. DAS181 is an inhaled therapy. In a recent China study of patients with severe COVID-19, DAS181 produced a significant improvement in all four patients. Ansun has raised $165 million from China investors including Sinopharm Healthcare Fund and Lilly Asia Ventures. More details....

Share this with colleagues:



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital